Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Warren Buffett's Big Biotech Bet Is 1 of His Riskiest Wagers Ever

VanEck Vectors Biotech ETF

First Trust Nasdaq Retail ETF

First Trust Consumer Staples AlphaDEX Fund

iShares Nasdaq Biotechnology ETF

iShares Evolved U.S. Innovative Healthcare ETF

Kroger

Warren Buffett took positions in Biogen and Kroger. Investors who want to follow Buffett's picking of these two value stocks can also play these ETFs as well.

Wanna Be a Value Investor? Follow Buffett & Play 2 ETF Areas

When it comes to ranking the greatest investors, Warren Buffett is among the best of the modern era.

Why Biogen Fits Well With Warren Buffett and Berkshire Hathaway, Even With Biotech Risks

Bristol-Myers

Does the potential of a home run for Biogen with its Alzheimer's disease candidate outweigh the strong lineup and pipeline that Bristol-Myers Squibb offers?

Better Buy: Biogen vs.  Bristol-Myers Squibb

Warren Buffett's holding company has disclosed its first biotechnology investment.

Warren Buffett's Berkshire Hathaway Dives Into Biotechnology

Warren Buffett's Berkshire Hathaway Inc  on Friday said it has taken a $549.1 million stake in Kroger Co , investing in the largest U.S. supermarket chain as smaller rivals struggle.

Buffett's Berkshire buys Kroger and Biogen, reduces Wells Fargo and Goldman stakes

Warren Buffett (Trades, Portfolio)’s $486 billion conglomerate, Berkshire Hathaway Inc.

Warren Buffett Buys Kroger, Biogen in 4th Quarter

Warren Buffett's Berkshire Hathaway Inc. BRK.A, +0.51% BRK.B, +0.15% started new stakes in Biogen Inc.

Berkshire Hathaway starts position in Biogen, Kroger while trimming Travelers

Amgen

Gilead Sciences

Amgen, Biogen, and Gilead Sciences have each transformed their early investors.

3 Biotech Stocks That Made Early Shareholders Millionaires

Biogen’s victory in a patent case involving its blockbuster multiple sclerosis drug is positive, but other uncertainties are waiting in the wings.

Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?

Shares of Eli Lilly and Roche slipped Monday after the pharmaceutical companies' experimental Alzheimer's treatments, solanezumab and gantenerumab, failed in a genetic form of the disease.
The post Pharma Giants Slide On Alzheimer's Failures — Taking Biogen With Them appeared first on Investor's Business Daily.

Pharma Giants Slide On Alzheimer's Failures — Taking Biogen With Them

Novartis

Vertex Pharmaceuticals

We examine three biotech companies' past performances and future outlooks.

3 Biotech Companies Analyzed

Biogen: Strong Prospects With A Low Valuation

The U.S. Patent and Trademark Office imparts a ruling in favor of Biogen (BIIB) over generic drugmaker Mylan to protect the patent of its best-selling multiple sclerosis drug, Tecfidera.

Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan

Investors cheered as the judge ruled in favor of Biogen in this long-awaited case.

Biogen Surges After Winning Crucial Multiple Sclerosis Drug Patent

A favorable patent ruling could translate to smoother sailing for Biogen's top-selling drug.

Why Biogen Shares Soared Today

Shares of Biogen Inc. BIIB, +16.73% rocketed 19% in trading on Wednesday after the Patent Trial and Appeal Board ruled in its favor on a patent challenge brought by Mylan Inc.

Biogen's stock jump 19% on Tecfidera patent ruling

Biogen Inc (NASDAQ: BIIB) shares were trading higher Wednesday following the issuing of a decision by the U.S.

Biogen Rallies On Tecfidera Patent Decision

Biogen stock rocketed Wednesday after reports suggested U.S. patent officials agreed to uphold the patent covering Tecfidera for several more years, an important multiple sclerosis drug.

Biogen Stock Rockets On Reports It Crushed A Mylan Patent Challenge

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q4 2019 Results - Earnings Call Transcript

Share repurchases helped enhance the pharmaceutical giant's results.

Biogen's Earnings Per Share Jumped 19% in Fourth Quarter

On Jan. 30 before the market opened, Biogen Inc. (NASDAQ:BIIB) reported its fourth-quarter and full-year earnings for 2019.

Biogen Reports Strong 4th-Quarter Earnings and Growth Potential

Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The company expects decline in sales and earnings in 2020.

Biogen (BIIB) Surpasses Q4 Earnings and Sales Estimates

Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter.

Biogen (BIIB) Q4 Earnings & Sales Beat Estimates

Shares of Biogen Inc. BIIB, +0.20% were up 2% after the company beat earnings expectations for the fourth quarter.

News for Biogen Stock (BIIB)